NCT02903381View on ClinicalTrials.gov

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

June 28, 2018

Study Completion Date

September 16, 2021

Conditions
Smoldering Multiple Myeloma
Interventions
DRUG

Nivolumab

Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and

DRUG

Lenalidomide

Oral, predetermined dosage, Days 1-21 of cycle 1-12

DRUG

Dexamethasone

Oral, Days 1, 8, 15 of cycle 1-6

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

Blood Cancer Research Partnership

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT02903381 - A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | Biotech Hunter | Biotech Hunter